Literature DB >> 27254747

Mortality and survival patterns of people living with HIV-2.

Boris Tchounga1, Didier K Ekouevi, Eric Balestre, François Dabis.   

Abstract

PURPOSE OF REVIEW: People living with HIV-2 infected usually initiate antiretroviral therapy (ART) at an advanced period in the course of their infection after a long asymptomatic period characterized by high CD4 cell count and thus at a relatively advanced age. In the new international context of early and universal ART initiation, the aim was to review survival patterns among HIV-2 infected patients, either on ART or not. RECENT
FINDINGS: Very few reports were published on mortality in people living with HIV-2 during the last 5 years. People living with HIV-2 experience high mortality rates although lower than people living with HIV-1 before ART initiation. They seem to survive longer regardless of the conditions of ART use. Mortality is associated with late presentation, male sex, CD4 cell count less than 500 cell/μl, high plasma viral load, hemoglobin rate less than 8 g/dl and body mass index less than 18 kg/m.
SUMMARY: People living with HIV-2 initiate ART later than HIV-1 and HIV duals, resulting in higher disease progression and mortality rate. The clinical management of HIV-2 infected patients should now include early diagnosis and treatment initiation as per international guidelines. Further research needs to explore the 'what to start' question and document specific causes of death in people living with HIV-2 and enrolled in care in Africa.

Entities:  

Mesh:

Year:  2016        PMID: 27254747      PMCID: PMC5055442          DOI: 10.1097/COH.0000000000000299

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  42 in total

1.  CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.

Authors:  Sophie Matheron; Florence Damond; Antoine Benard; Audrey Taieb; Pauline Campa; Gilles Peytavin; Sophie Pueyo; Francoise Brun-Vezinet; Genevieve Chene
Journal:  AIDS       Date:  2006-02-14       Impact factor: 4.177

2.  Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

Authors:  Antoine Benard; Ard van Sighem; Audrey Taieb; Emilia Valadas; Jean Ruelle; Vicente Soriano; Alexandra Calmy; Claudia Balotta; Florence Damond; Françoise Brun-Vezinet; Geneviève Chene; Sophie Matheron
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

3.  Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

Authors:  Adam MacNeil; Abdoulaye Dieng Sarr; Jean-Louis Sankalé; Seema Thakore Meloni; Souleymane Mboup; Phyllis Kanki
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa.

Authors:  A G Poulsen; B Kvinesdal; P Aaby; K Mølbak; K Frederiksen; F Dias; E Lauritzen
Journal:  Lancet       Date:  1989-04-15       Impact factor: 79.321

5.  Differential effects of sex in a West African cohort of HIV-1, HIV-2 and HIV-1/2 dually infected patients: men are worse off.

Authors:  Sanne Jespersen; Bo Langhoff Hønge; Joakim Esbjörnsson; Candida Medina; David da Silva Té; Faustino Gomes Correira; Alex Lund Laursen; Lars Østergaard; Andreas Andersen; Peter Aaby; Christian Erikstrup; Christian Wejse
Journal:  Trop Med Int Health       Date:  2015-12-21       Impact factor: 2.622

6.  Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village.

Authors:  Maarten F Schim van der Loeff; Natasha Larke; Steve Kaye; Neil Berry; Koya Ariyoshi; Abraham Alabi; Carla van Tienen; Aleksandra Leligdowicz; Ramu Sarge-Njie; Zacharias da Silva; Assan Jaye; Dominique Ricard; Tim Vincent; Sarah Rowland Jones; Peter Aaby; Shabbar Jaffar; Hilton Whittle
Journal:  Retrovirology       Date:  2010-05-19       Impact factor: 4.602

7.  Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.

Authors:  Antoine Bénard; Florence Damond; Pauline Campa; Gilles Peytavin; Diane Descamps; Caroline Lascoux-Combes; Audrey Taieb; François Simon; Brigitte Autran; Françoise Brun-Vézinet; Geneviève Chêne; Sophie Matheron
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

8.  Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia.

Authors:  Ingrid Peterson; Oluwatoyin Togun; Thushan de Silva; Francis Oko; Sarah Rowland-Jones; Assan Jaye; Kevin Peterson
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

9.  Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic.

Authors:  Euridice Martinez-Steele; Akum Aveika Awasana; Tumani Corrah; Saihou Sabally; Marianne van der Sande; Assan Jaye; Toyin Togun; Ramu Sarge-Njie; Samuel J McConkey; Hilton Whittle; Maarten F Schim van der Loeff
Journal:  AIDS       Date:  2007-01-30       Impact factor: 4.177

Review 10.  Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis.

Authors:  Samuel Nyamweya; Andrea Hegedus; Assan Jaye; Sarah Rowland-Jones; Katie L Flanagan; Derek C Macallan
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

View more
  9 in total

Review 1.  Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.

Authors:  M T Boswell; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2019-03-21       Impact factor: 4.330

2.  Specific Guanosines in the HIV-2 Leader RNA are Essential for Efficient Viral Genome Packaging.

Authors:  Chijioke N Umunnakwe; Alice Duchon; Olga A Nikolaitchik; Sheikh Abdul Rahman; Yang Liu; Jianbo Chen; Sheldon Tai; Vinay K Pathak; Wei-Shau Hu
Journal:  J Mol Biol       Date:  2020-11-19       Impact factor: 6.151

3.  Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection.

Authors:  Marco Iannetta; Stéphane Isnard; Jennifer Manuzak; Jean-Baptiste Guillerme; Mathilde Notin; Karine Bailly; Muriel Andrieu; Sonia Amraoui; Lene Vimeux; Suzanne Figueiredo; Bénédicte Charmeteau-de Muylder; Laura Vaton; Etienne X Hatton; Assia Samri; Brigitte Autran; Rodolphe Thiébaut; Nathalie Chaghil; David Glohi; Charlotte Charpentier; Diane Descamps; Françoise Brun-Vézinet; Sophie Matheron; Remi Cheynier; Anne Hosmalin
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

4.  Low Postseroconversion CD4+ T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection.

Authors:  Joakim Esbjörnsson; Patrik Medstrand; Angelica A Palm; Philippe Lemey; Marianne Jansson; Fredrik Månsson; Anders Kvist; Zsófia Szojka; Antonio Biague; Zacarias José da Silva; Sarah L Rowland-Jones; Hans Norrgren
Journal:  mBio       Date:  2019-01-08       Impact factor: 7.867

Review 5.  HIV-2 as a model to identify a functional HIV cure.

Authors:  Joakim Esbjörnsson; Marianne Jansson; Sanne Jespersen; Fredrik Månsson; Bo L Hønge; Jacob Lindman; Candida Medina; Zacarias J da Silva; Hans Norrgren; Patrik Medstrand; Sarah L Rowland-Jones; Christian Wejse
Journal:  AIDS Res Ther       Date:  2019-09-05       Impact factor: 2.250

6.  Transcription Start Site Heterogeneity and Preferential Packaging of Specific Full-Length RNA Species Are Conserved Features of Primate Lentiviruses.

Authors:  Jonathan M O Rawson; Olga A Nikolaitchik; Saurabh Shakya; Brandon F Keele; Vinay K Pathak; Wei-Shau Hu
Journal:  Microbiol Spectr       Date:  2022-06-23

Review 7.  HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options.

Authors:  S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge
Journal:  AIDS Res Ther       Date:  2020-02-04       Impact factor: 2.250

Review 8.  COVID-19 Pandemic: Public Health Risk Assessment and Risk Mitigation Strategies.

Authors:  Dae-Young Kim; Surendra Krushna Shinde; Saifullah Lone; Ramasubba Reddy Palem; Gajanan Sampatrao Ghodake
Journal:  J Pers Med       Date:  2021-11-23

9.  Human immunodeficiency virus (HIV) type 1 genetic diversity in HIV positive individuals on antiretroviral therapy in a cross-sectional study conducted in Teso, Western Kenya.

Authors:  Maureen Adhiambo; Olipher Makwaga; Ferdinard Adungo; Humphrey Kimani; David Hughes Mulama; Jackson Cheruiyot Korir; Matilu Mwau
Journal:  Pan Afr Med J       Date:  2021-04-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.